The venture capital manager Inveready, a CataloniaBio & HealthTech member, has led a € 3 million round for Atlas Molecular Pharma (Atlas). It has been completed together with the public entities CDTI and EZTEN, and the participation of the company’s current partners.
With this investment, Atlas, created with the aim of developing new pharmacological chaperones for the treatment of rare metabolic diseases, will begin a Phase I study and a Phase II clinical trial to evaluate the drug's effectiveness in patients with PEC, which will be conducted in the United States. Completion of studies should allow access to the FDA's accelerated approval program to bring the lead candidate (ATL-001) to patients and begin commercialization.
"The preclinical results of ATL-001 are promising and significantly improve the disease phenotype," said Antonio Herce, an associate of Inveready in Life Sciences.
Inveready has carried out the operation through the Inveready Biotech III fund, with a volume of 30 million. The manager has more than 400 million in assets through its various vehicles, not all dedicated to the health sciences.
Photo: Antonio Herce, associate of Inveready in Life Sciences
You may also be interested in:
Comments